The EU is prepared to tackle ongoing pandemic challenges, says EMA chief | Nieuws | Europees Parlement

 

The EU is prepared to tackle ongoing pandemic challenges, says EMA chief 

Persbericht 
 
 

Health MEPs quizzed the EMA’s Executive Director on Tuesday on the current situation around COVID-19 vaccines and therapeutics, as well as the Agency’s future role.

In light of increasing COVID-19 cases across the EU and concerns raised by a new variant, members of the Environment, Public Health and Food Safety Committee focused the debate on COVID-19 vaccines, recent developments in COVID-19 therapeutics and the Agency’s capacity to deal with current and future challenges. MEPs asked whether the agency is prepared to deal with new variants, about the use and effectiveness of booster vaccines, clinical trials transparency and coordination with European and international counterparts, including the new Health Emergency Preparedness and Response Authority (HERA).


Emer Cooke, Executive Director of the European Medicines Agency (EMA) reassured MEPs that the EMA is prepared to deal with the current challenges posed by the pandemic. Existing vaccines have remained effective until now, with studies showing that an additional dose or booster ensures extended immunity, she added. Should a scientific decision be taken to adapt them, the Agency already has in place guidance for manufacturers that plan to modify vaccines to address variants. The agency also has a legal framework to authorise adapted vaccines more quickly, which would ensure they are approved within a 3-4 months period.


The EMA recently recommended that a booster dose of the two mRNA-based COVID-19 vaccines (Comirnaty-BioNTech/Pfizer and Spikevax - Moderna) may be given to people with severely weakened immune systems as well as the general population over 18 years old, said Emer Cooke. Member states decide how these boosters should be rolled out depending on their vaccination campaigns and the capacity of their national health systems.


Regarding clinical trials, Ms Cooke confirmed that the EMA is committed to being transparent in publishing data, also in view of the application of the new requirements under the clinical trials regulation from the end of January 2022. On coordination with HERA, the EMA is currently preparing a memorandum of understanding, which will clearly outline the responsibilities of the two bodies and ensure they coordinate effectively.


With regard to the EMA’s capacity to deal with its reinforced role, Ms Cooke informed MEPs that the Agency is still evaluating the impact of its new tasks. However, the general situation is a concern, with the workload constantly growing since 2014 and the needs of human resources not being matched with financial resources.


Background


The Environment, Public Health and Food Safety MEPs hold annual exchanges with leaders of EU agencies within the committee’s fields of expertise. Parliament and Council also recently reached a deal for a stronger role for the Agency following lessons learned from the pandemic.

 
  • Direct naar de inhoud van de pagina (druk op "Enter")
  • Direct naar de inhoud van de pagina (druk op "Enter")Direct naar de inhoud van de pagina (druk op "Enter")
  • Rechtstreeks naar talenmenu (druk op "Enter")
  • Rechtstreeks naar talenmenu (druk op "Enter")Rechtstreeks naar talenmenu (druk op "Enter")
  • Rechtstreeks naar zoekmenu (druk op "Enter")
  • Rechtstreeks naar zoekmenu (druk op "Enter")Rechtstreeks naar zoekmenu (druk op "Enter")
  • BG - български
  • BG - български BG - българскиBG - български
  • ES - español
  • ES - español ES - españolES - español
  • CS - čeština
  • CS - čeština CS - češtinaCS - čeština
  • DA - dansk
  • DA - dansk DA - danskDA - dansk
  • DE - Deutsch
  • DE - Deutsch DE - DeutschDE - Deutsch
  • ET - eesti keel
  • ET - eesti keel ET - eesti keelET - eesti keel
  • EL - ελληνικά
  • EL - ελληνικά EL - ελληνικάEL - ελληνικά
  • EN - English
  • EN - English EN - EnglishEN - English
  • FR - français
  • FR - français FR - françaisFR - français
  • GA - Gaeilge
  • GA - Gaeilge GA - GaeilgeGA - Gaeilge
  • HR - hrvatski
  • HR - hrvatski HR - hrvatskiHR - hrvatski
  • IT - italiano
  • IT - italiano IT - italianoIT - italiano
  • LV - latviešu valoda
  • LV - latviešu valoda LV - latviešu valodaLV - latviešu valoda
  • LT - lietuvių kalba
  • LT - lietuvių kalba LT - lietuvių kalbaLT - lietuvių kalba
  • HU - magyar
  • HU - magyar HU - magyarHU - magyar
  • MT - Malti
  • MT - Malti MT - MaltiMT - Malti
  • NL - Nederlands
  • NL - Nederlands NL - NederlandsNL - Nederlands
  • PL - polski
  • PL - polski PL - polskiPL - polski
  • PT - português
  • PT - português PT - portuguêsPT - português
  • RO - română
  • RO - română RO - românăRO - română
  • SK - slovenčina
  • SK - slovenčina SK - slovenčinaSK - slovenčina
  • SL - slovenščina
  • SL - slovenščina SL - slovenščinaSL - slovenščina
  • FI - suomi
  • FI - suomi FI - suomiFI - suomi
  • SV - svenska
  • SV - svenska SV - svenskaSV - svenska
  • Naar pagina gaan Nieuws
  • Naar pagina gaan Nieuws Naar pagina gaan Nieuws Naar pagina gaanNieuws
  • Naar pagina gaan Leden
  • Naar pagina gaan Leden Naar pagina gaan Leden Naar pagina gaanLeden
  • Naar pagina gaan Over het Parlement
  • Naar pagina gaan Over het Parlement Naar pagina gaan Over het Parlement Naar pagina gaanOver het Parlement
  • Naar pagina gaan Plenaire vergadering
  • Naar pagina gaan Plenaire vergadering Naar pagina gaan Plenaire vergadering Naar pagina gaanPlenaire vergadering
  • Naar pagina gaan Commissies
  • Naar pagina gaan Commissies Naar pagina gaan Commissies Naar pagina gaanCommissies
  • Naar pagina gaan Delegaties
  • Naar pagina gaan Delegaties Naar pagina gaan Delegaties Naar pagina gaanDelegaties
  • Andere websites Andere websites
  • Naar pagina gaan Multimedia Centre
  • Naar pagina gaan Multimedia Centre Naar pagina gaan Multimedia Centre Naar pagina gaanMultimedia Centre
  • Naar pagina gaan Webpagina van de Voorzitter
  • Naar pagina gaan Webpagina van de Voorzitter Naar pagina gaan Webpagina van de Voorzitter Naar pagina gaanWebpagina van de Voorzitter
  • Naar pagina gaan Secretariaat-generaal
  • Naar pagina gaan Secretariaat-generaal Naar pagina gaan Secretariaat-generaal Naar pagina gaanSecretariaat-generaal
  • Naar pagina gaan Think tank
  • Naar pagina gaan Think tank Naar pagina gaan Think tank Naar pagina gaanThink tank
  • Naar pagina gaan EP Newshub
  • Naar pagina gaan EP Newshub Naar pagina gaan EP Newshub Naar pagina gaanEP Newshub
  • Naar pagina gaan Tot uw dienst
  • Naar pagina gaan Tot uw dienst Naar pagina gaan Tot uw dienst Naar pagina gaanTot uw dienst
  • Naar pagina gaan Bezoeken
  • Naar pagina gaan Bezoeken Naar pagina gaan Bezoeken Naar pagina gaanBezoeken
  • Naar pagina gaan Legislative train
  • Naar pagina gaan Legislative train Naar pagina gaan Legislative train Naar pagina gaanLegislative train
  • Naar pagina gaan Contracten en subsidies
  • Naar pagina gaan Contracten en subsidies Naar pagina gaan Contracten en subsidies Naar pagina gaanContracten en subsidies
  • Naar pagina gaan Registreren
  • Naar pagina gaan Registreren Naar pagina gaan Registreren Naar pagina gaanRegistreren
    Nieuws Europees Parlement NieuwsNieuws Europees Parlement Europees Parlement Menu Menu
  • Nieuws
  • Nieuws Nieuws Nieuws
  • Naar pagina gaan Startpagina
  • Naar pagina gaan Startpagina Naar pagina gaan Startpagina Naar pagina gaanStartpagina
  • Naar pagina gaan Europese zaken
  • Naar pagina gaan Europese zaken Naar pagina gaan Europese zaken Naar pagina gaanEuropese zaken
  • Naar pagina gaan Wereld
  • Naar pagina gaan Wereld Naar pagina gaan Wereld Naar pagina gaanWereld
  • Naar pagina gaan Economie
  • Naar pagina gaan Economie Naar pagina gaan Economie Naar pagina gaanEconomie
  • Naar pagina gaan Maatschappij
  • Naar pagina gaan Maatschappij Naar pagina gaan Maatschappij Naar pagina gaanMaatschappij
  • Naar pagina gaan Veiligheid
  • Naar pagina gaan Veiligheid Naar pagina gaan Veiligheid Naar pagina gaanVeiligheid
  • Pers
  • Pers Pers Pers
  • Naar pagina gaan Startpagina
  • Naar pagina gaan Startpagina Naar pagina gaan Startpagina Naar pagina gaanStartpagina
  • Naar pagina gaan Accreditatie
  • Naar pagina gaan Accreditatie Naar pagina gaan Accreditatie Naar pagina gaanAccreditatie
  • Naar pagina gaan Online persdossier
  • Naar pagina gaan Online persdossier Naar pagina gaan Online persdossier Naar pagina gaanOnline persdossier
  • Naar pagina gaan Contact
  • Naar pagina gaan Contact Naar pagina gaan Contact Naar pagina gaanContact
  • Agenda
  • Agenda Agenda Agenda
  • Naar pagina gaan Hoogtepunten
  • Naar pagina gaan Hoogtepunten Naar pagina gaan Hoogtepunten Naar pagina gaanHoogtepunten
  • Naar pagina gaan Wekelijkse agenda
  • Naar pagina gaan Wekelijkse agenda Naar pagina gaan Wekelijkse agenda Naar pagina gaanWekelijkse agenda
  • Naar pagina gaan Briefing
  • Naar pagina gaan Briefing Naar pagina gaan Briefing Naar pagina gaanBriefing
  • Veelgestelde vragen
  • Veelgestelde vragen Veelgestelde vragen Veelgestelde vragen
  • #EuropeanenTegenCovid19
  • #EuropeanenTegenCovid19 #EuropeanenTegenCovid19 #EuropeanenTegenCovid19Naar het zoekveld
    Zoekopdracht starten Europees Parlement
    Pers   > Huidige pagina: The EU is prepared to tackle ongoing pandemic challenges, says EMA chief  
    Pers   > Pers  Pers > Huidige pagina: The EU is prepared to tackle ongoing pandemic challenges, says EMA chief   Huidige pagina: The EU is prepared to tackle ongoing pandemic challenges, says EMA chief   Huidige pagina:The EU is prepared to tackle ongoing pandemic challenges, says EMA chief  Pers  Pers >
     

    The EU is prepared to tackle ongoing pandemic challenges, says EMA chief 

    Persbericht 
     
     

    Health MEPs quizzed the EMA’s Executive Director on Tuesday on the current situation around COVID-19 vaccines and therapeutics, as well as the Agency’s future role.

    In light of increasing COVID-19 cases across the EU and concerns raised by a new variant, members of the Environment, Public Health and Food Safety Committee focused the debate on COVID-19 vaccines, recent developments in COVID-19 therapeutics and the Agency’s capacity to deal with current and future challenges. MEPs asked whether the agency is prepared to deal with new variants, about the use and effectiveness of booster vaccines, clinical trials transparency and coordination with European and international counterparts, including the new Health Emergency Preparedness and Response Authority (HERA).


    Emer Cooke, Executive Director of the European Medicines Agency (EMA) reassured MEPs that the EMA is prepared to deal with the current challenges posed by the pandemic. Existing vaccines have remained effective until now, with studies showing that an additional dose or booster ensures extended immunity, she added. Should a scientific decision be taken to adapt them, the Agency already has in place guidance for manufacturers that plan to modify vaccines to address variants. The agency also has a legal framework to authorise adapted vaccines more quickly, which would ensure they are approved within a 3-4 months period.


    The EMA recently recommended that a booster dose of the two mRNA-based COVID-19 vaccines (Comirnaty-BioNTech/Pfizer and Spikevax - Moderna) may be given to people with severely weakened immune systems as well as the general population over 18 years old, said Emer Cooke. Member states decide how these boosters should be rolled out depending on their vaccination campaigns and the capacity of their national health systems.


    Regarding clinical trials, Ms Cooke confirmed that the EMA is committed to being transparent in publishing data, also in view of the application of the new requirements under the clinical trials regulation from the end of January 2022. On coordination with HERA, the EMA is currently preparing a memorandum of understanding, which will clearly outline the responsibilities of the two bodies and ensure they coordinate effectively.


    With regard to the EMA’s capacity to deal with its reinforced role, Ms Cooke informed MEPs that the Agency is still evaluating the impact of its new tasks. However, the general situation is a concern, with the workload constantly growing since 2014 and the needs of human resources not being matched with financial resources.


    Background


    The Environment, Public Health and Food Safety MEPs hold annual exchanges with leaders of EU agencies within the committee’s fields of expertise. Parliament and Council also recently reached a deal for a stronger role for the Agency following lessons learned from the pandemic.

     
     

    The EU is prepared to tackle ongoing pandemic challenges, says EMA chief 

    Persbericht 
     
     

    The EU is prepared to tackle ongoing pandemic challenges, says EMA chief 

    Persbericht 
     
     
     

    The EU is prepared to tackle ongoing pandemic challenges, says EMA chief 

    Persbericht 
     

    The EU is prepared to tackle ongoing pandemic challenges, says EMA chief 

    Persbericht 
     

    The EU is prepared to tackle ongoing pandemic challenges, says EMA chief 

    Persbericht 
     

    The EU is prepared to tackle ongoing pandemic challenges, says EMA chief 

    The EU is prepared to tackle ongoing pandemic challenges, says EMA chief 
    The EU is prepared to tackle ongoing pandemic challenges, says EMA chief 
    Persbericht 
     
    Persbericht 
    Persbericht  ENVI  ENVIENVI 
     
     
     

    Health MEPs quizzed the EMA’s Executive Director on Tuesday on the current situation around COVID-19 vaccines and therapeutics, as well as the Agency’s future role.

    In light of increasing COVID-19 cases across the EU and concerns raised by a new variant, members of the Environment, Public Health and Food Safety Committee focused the debate on COVID-19 vaccines, recent developments in COVID-19 therapeutics and the Agency’s capacity to deal with current and future challenges. MEPs asked whether the agency is prepared to deal with new variants, about the use and effectiveness of booster vaccines, clinical trials transparency and coordination with European and international counterparts, including the new Health Emergency Preparedness and Response Authority (HERA).


    Emer Cooke, Executive Director of the European Medicines Agency (EMA) reassured MEPs that the EMA is prepared to deal with the current challenges posed by the pandemic. Existing vaccines have remained effective until now, with studies showing that an additional dose or booster ensures extended immunity, she added. Should a scientific decision be taken to adapt them, the Agency already has in place guidance for manufacturers that plan to modify vaccines to address variants. The agency also has a legal framework to authorise adapted vaccines more quickly, which would ensure they are approved within a 3-4 months period.


    The EMA recently recommended that a booster dose of the two mRNA-based COVID-19 vaccines (Comirnaty-BioNTech/Pfizer and Spikevax - Moderna) may be given to people with severely weakened immune systems as well as the general population over 18 years old, said Emer Cooke. Member states decide how these boosters should be rolled out depending on their vaccination campaigns and the capacity of their national health systems.


    Regarding clinical trials, Ms Cooke confirmed that the EMA is committed to being transparent in publishing data, also in view of the application of the new requirements under the clinical trials regulation from the end of January 2022. On coordination with HERA, the EMA is currently preparing a memorandum of understanding, which will clearly outline the responsibilities of the two bodies and ensure they coordinate effectively.


    With regard to the EMA’s capacity to deal with its reinforced role, Ms Cooke informed MEPs that the Agency is still evaluating the impact of its new tasks. However, the general situation is a concern, with the workload constantly growing since 2014 and the needs of human resources not being matched with financial resources.


    Background


    The Environment, Public Health and Food Safety MEPs hold annual exchanges with leaders of EU agencies within the committee’s fields of expertise. Parliament and Council also recently reached a deal for a stronger role for the Agency following lessons learned from the pandemic.

     
     

    Health MEPs quizzed the EMA’s Executive Director on Tuesday on the current situation around COVID-19 vaccines and therapeutics, as well as the Agency’s future role.

    In light of increasing COVID-19 cases across the EU and concerns raised by a new variant, members of the Environment, Public Health and Food Safety Committee focused the debate on COVID-19 vaccines, recent developments in COVID-19 therapeutics and the Agency’s capacity to deal with current and future challenges. MEPs asked whether the agency is prepared to deal with new variants, about the use and effectiveness of booster vaccines, clinical trials transparency and coordination with European and international counterparts, including the new Health Emergency Preparedness and Response Authority (HERA).


    Emer Cooke, Executive Director of the European Medicines Agency (EMA) reassured MEPs that the EMA is prepared to deal with the current challenges posed by the pandemic. Existing vaccines have remained effective until now, with studies showing that an additional dose or booster ensures extended immunity, she added. Should a scientific decision be taken to adapt them, the Agency already has in place guidance for manufacturers that plan to modify vaccines to address variants. The agency also has a legal framework to authorise adapted vaccines more quickly, which would ensure they are approved within a 3-4 months period.


    The EMA recently recommended that a booster dose of the two mRNA-based COVID-19 vaccines (Comirnaty-BioNTech/Pfizer and Spikevax - Moderna) may be given to people with severely weakened immune systems as well as the general population over 18 years old, said Emer Cooke. Member states decide how these boosters should be rolled out depending on their vaccination campaigns and the capacity of their national health systems.


    Regarding clinical trials, Ms Cooke confirmed that the EMA is committed to being transparent in publishing data, also in view of the application of the new requirements under the clinical trials regulation from the end of January 2022. On coordination with HERA, the EMA is currently preparing a memorandum of understanding, which will clearly outline the responsibilities of the two bodies and ensure they coordinate effectively.


    With regard to the EMA’s capacity to deal with its reinforced role, Ms Cooke informed MEPs that the Agency is still evaluating the impact of its new tasks. However, the general situation is a concern, with the workload constantly growing since 2014 and the needs of human resources not being matched with financial resources.


    Background


    The Environment, Public Health and Food Safety MEPs hold annual exchanges with leaders of EU agencies within the committee’s fields of expertise. Parliament and Council also recently reached a deal for a stronger role for the Agency following lessons learned from the pandemic.

     
     
     

    Deel deze pagina: 

    Deel deze pagina: 
    Deel deze pagina: 
  • Facebook Facebook 
  • Twitter Twitter 
  • LinkedIn LinkedIn 
  • Whatsapp Whatsapp 

    Health MEPs quizzed the EMA’s Executive Director on Tuesday on the current situation around COVID-19 vaccines and therapeutics, as well as the Agency’s future role.

    In light of increasing COVID-19 cases across the EU and concerns raised by a new variant, members of the Environment, Public Health and Food Safety Committee focused the debate on COVID-19 vaccines, recent developments in COVID-19 therapeutics and the Agency’s capacity to deal with current and future challenges. MEPs asked whether the agency is prepared to deal with new variants, about the use and effectiveness of booster vaccines, clinical trials transparency and coordination with European and international counterparts, including the new Health Emergency Preparedness and Response Authority (HERA).


    Emer Cooke, Executive Director of the European Medicines Agency (EMA) reassured MEPs that the EMA is prepared to deal with the current challenges posed by the pandemic. Existing vaccines have remained effective until now, with studies showing that an additional dose or booster ensures extended immunity, she added. Should a scientific decision be taken to adapt them, the Agency already has in place guidance for manufacturers that plan to modify vaccines to address variants. The agency also has a legal framework to authorise adapted vaccines more quickly, which would ensure they are approved within a 3-4 months period.


    The EMA recently recommended that a booster dose of the two mRNA-based COVID-19 vaccines (Comirnaty-BioNTech/Pfizer and Spikevax - Moderna) may be given to people with severely weakened immune systems as well as the general population over 18 years old, said Emer Cooke. Member states decide how these boosters should be rolled out depending on their vaccination campaigns and the capacity of their national health systems.


    Regarding clinical trials, Ms Cooke confirmed that the EMA is committed to being transparent in publishing data, also in view of the application of the new requirements under the clinical trials regulation from the end of January 2022. On coordination with HERA, the EMA is currently preparing a memorandum of understanding, which will clearly outline the responsibilities of the two bodies and ensure they coordinate effectively.


    With regard to the EMA’s capacity to deal with its reinforced role, Ms Cooke informed MEPs that the Agency is still evaluating the impact of its new tasks. However, the general situation is a concern, with the workload constantly growing since 2014 and the needs of human resources not being matched with financial resources.


    Background


    The Environment, Public Health and Food Safety MEPs hold annual exchanges with leaders of EU agencies within the committee’s fields of expertise. Parliament and Council also recently reached a deal for a stronger role for the Agency following lessons learned from the pandemic.

    Health MEPs quizzed the EMA’s Executive Director on Tuesday on the current situation around COVID-19 vaccines and therapeutics, as well as the Agency’s future role.

    In light of increasing COVID-19 cases across the EU and concerns raised by a new variant, members of the Environment, Public Health and Food Safety Committee focused the debate on COVID-19 vaccines, recent developments in COVID-19 therapeutics and the Agency’s capacity to deal with current and future challenges. MEPs asked whether the agency is prepared to deal with new variants, about the use and effectiveness of booster vaccines, clinical trials transparency and coordination with European and international counterparts, including the new Health Emergency Preparedness and Response Authority (HERA).


    Emer Cooke, Executive Director of the European Medicines Agency (EMA) reassured MEPs that the EMA is prepared to deal with the current challenges posed by the pandemic. Existing vaccines have remained effective until now, with studies showing that an additional dose or booster ensures extended immunity, she added. Should a scientific decision be taken to adapt them, the Agency already has in place guidance for manufacturers that plan to modify vaccines to address variants. The agency also has a legal framework to authorise adapted vaccines more quickly, which would ensure they are approved within a 3-4 months period.


    The EMA recently recommended that a booster dose of the two mRNA-based COVID-19 vaccines (Comirnaty-BioNTech/Pfizer and Spikevax - Moderna) may be given to people with severely weakened immune systems as well as the general population over 18 years old, said Emer Cooke. Member states decide how these boosters should be rolled out depending on their vaccination campaigns and the capacity of their national health systems.


    Regarding clinical trials, Ms Cooke confirmed that the EMA is committed to being transparent in publishing data, also in view of the application of the new requirements under the clinical trials regulation from the end of January 2022. On coordination with HERA, the EMA is currently preparing a memorandum of understanding, which will clearly outline the responsibilities of the two bodies and ensure they coordinate effectively.


    With regard to the EMA’s capacity to deal with its reinforced role, Ms Cooke informed MEPs that the Agency is still evaluating the impact of its new tasks. However, the general situation is a concern, with the workload constantly growing since 2014 and the needs of human resources not being matched with financial resources.


    Background


    The Environment, Public Health and Food Safety MEPs hold annual exchanges with leaders of EU agencies within the committee’s fields of expertise. Parliament and Council also recently reached a deal for a stronger role for the Agency following lessons learned from the pandemic.

    Health MEPs quizzed the EMA’s Executive Director on Tuesday on the current situation around COVID-19 vaccines and therapeutics, as well as the Agency’s future role.

    In light of increasing COVID-19 cases across the EU and concerns raised by a new variant, members of the Environment, Public Health and Food Safety Committee focused the debate on COVID-19 vaccines, recent developments in COVID-19 therapeutics and the Agency’s capacity to deal with current and future challenges. MEPs asked whether the agency is prepared to deal with new variants, about the use and effectiveness of booster vaccines, clinical trials transparency and coordination with European and international counterparts, including the new Health Emergency Preparedness and Response Authority (HERA).


    Emer Cooke, Executive Director of the European Medicines Agency (EMA) reassured MEPs that the EMA is prepared to deal with the current challenges posed by the pandemic. Existing vaccines have remained effective until now, with studies showing that an additional dose or booster ensures extended immunity, she added. Should a scientific decision be taken to adapt them, the Agency already has in place guidance for manufacturers that plan to modify vaccines to address variants. The agency also has a legal framework to authorise adapted vaccines more quickly, which would ensure they are approved within a 3-4 months period.


    The EMA recently recommended that a booster dose of the two mRNA-based COVID-19 vaccines (Comirnaty-BioNTech/Pfizer and Spikevax - Moderna) may be given to people with severely weakened immune systems as well as the general population over 18 years old, said Emer Cooke. Member states decide how these boosters should be rolled out depending on their vaccination campaigns and the capacity of their national health systems.


    Regarding clinical trials, Ms Cooke confirmed that the EMA is committed to being transparent in publishing data, also in view of the application of the new requirements under the clinical trials regulation from the end of January 2022. On coordination with HERA, the EMA is currently preparing a memorandum of understanding, which will clearly outline the responsibilities of the two bodies and ensure they coordinate effectively.


    With regard to the EMA’s capacity to deal with its reinforced role, Ms Cooke informed MEPs that the Agency is still evaluating the impact of its new tasks. However, the general situation is a concern, with the workload constantly growing since 2014 and the needs of human resources not being matched with financial resources.


    Background


    The Environment, Public Health and Food Safety MEPs hold annual exchanges with leaders of EU agencies within the committee’s fields of expertise. Parliament and Council also recently reached a deal for a stronger role for the Agency following lessons learned from the pandemic.

    Health MEPs quizzed the EMA’s Executive Director on Tuesday on the current situation around COVID-19 vaccines and therapeutics, as well as the Agency’s future role.

    Health MEPs quizzed the EMA’s Executive Director on Tuesday on the current situation around COVID-19 vaccines and therapeutics, as well as the Agency’s future role.

    Health MEPs quizzed the EMA’s Executive Director on Tuesday on the current situation around COVID-19 vaccines and therapeutics, as well as the Agency’s future role.

    Health MEPs quizzed the EMA’s Executive Director on Tuesday on the current situation around COVID-19 vaccines and therapeutics, as well as the Agency’s future role.

    In light of increasing COVID-19 cases across the EU and concerns raised by a new variant, members of the Environment, Public Health and Food Safety Committee focused the debate on COVID-19 vaccines, recent developments in COVID-19 therapeutics and the Agency’s capacity to deal with current and future challenges. MEPs asked whether the agency is prepared to deal with new variants, about the use and effectiveness of booster vaccines, clinical trials transparency and coordination with European and international counterparts, including the new Health Emergency Preparedness and Response Authority (HERA).


    Emer Cooke, Executive Director of the European Medicines Agency (EMA) reassured MEPs that the EMA is prepared to deal with the current challenges posed by the pandemic. Existing vaccines have remained effective until now, with studies showing that an additional dose or booster ensures extended immunity, she added. Should a scientific decision be taken to adapt them, the Agency already has in place guidance for manufacturers that plan to modify vaccines to address variants. The agency also has a legal framework to authorise adapted vaccines more quickly, which would ensure they are approved within a 3-4 months period.


    The EMA recently recommended that a booster dose of the two mRNA-based COVID-19 vaccines (Comirnaty-BioNTech/Pfizer and Spikevax - Moderna) may be given to people with severely weakened immune systems as well as the general population over 18 years old, said Emer Cooke. Member states decide how these boosters should be rolled out depending on their vaccination campaigns and the capacity of their national health systems.


    Regarding clinical trials, Ms Cooke confirmed that the EMA is committed to being transparent in publishing data, also in view of the application of the new requirements under the clinical trials regulation from the end of January 2022. On coordination with HERA, the EMA is currently preparing a memorandum of understanding, which will clearly outline the responsibilities of the two bodies and ensure they coordinate effectively.


    With regard to the EMA’s capacity to deal with its reinforced role, Ms Cooke informed MEPs that the Agency is still evaluating the impact of its new tasks. However, the general situation is a concern, with the workload constantly growing since 2014 and the needs of human resources not being matched with financial resources.


    Background


    The Environment, Public Health and Food Safety MEPs hold annual exchanges with leaders of EU agencies within the committee’s fields of expertise. Parliament and Council also recently reached a deal for a stronger role for the Agency following lessons learned from the pandemic.

    In light of increasing COVID-19 cases across the EU and concerns raised by a new variant, members of the Environment, Public Health and Food Safety Committee focused the debate on COVID-19 vaccines, recent developments in COVID-19 therapeutics and the Agency’s capacity to deal with current and future challenges. MEPs asked whether the agency is prepared to deal with new variants, about the use and effectiveness of booster vaccines, clinical trials transparency and coordination with European and international counterparts, including the new Health Emergency Preparedness and Response Authority (HERA).


    Emer Cooke, Executive Director of the European Medicines Agency (EMA) reassured MEPs that the EMA is prepared to deal with the current challenges posed by the pandemic. Existing vaccines have remained effective until now, with studies showing that an additional dose or booster ensures extended immunity, she added. Should a scientific decision be taken to adapt them, the Agency already has in place guidance for manufacturers that plan to modify vaccines to address variants. The agency also has a legal framework to authorise adapted vaccines more quickly, which would ensure they are approved within a 3-4 months period.


    The EMA recently recommended that a booster dose of the two mRNA-based COVID-19 vaccines (Comirnaty-BioNTech/Pfizer and Spikevax - Moderna) may be given to people with severely weakened immune systems as well as the general population over 18 years old, said Emer Cooke. Member states decide how these boosters should be rolled out depending on their vaccination campaigns and the capacity of their national health systems.


    Regarding clinical trials, Ms Cooke confirmed that the EMA is committed to being transparent in publishing data, also in view of the application of the new requirements under the clinical trials regulation from the end of January 2022. On coordination with HERA, the EMA is currently preparing a memorandum of understanding, which will clearly outline the responsibilities of the two bodies and ensure they coordinate effectively.


    With regard to the EMA’s capacity to deal with its reinforced role, Ms Cooke informed MEPs that the Agency is still evaluating the impact of its new tasks. However, the general situation is a concern, with the workload constantly growing since 2014 and the needs of human resources not being matched with financial resources.


    Background


    The Environment, Public Health and Food Safety MEPs hold annual exchanges with leaders of EU agencies within the committee’s fields of expertise. Parliament and Council also recently reached a deal for a stronger role for the Agency following lessons learned from the pandemic.

    In light of increasing COVID-19 cases across the EU and concerns raised by a new variant, members of the Environment, Public Health and Food Safety Committee focused the debate on COVID-19 vaccines, recent developments in COVID-19 therapeutics and the Agency’s capacity to deal with current and future challenges. MEPs asked whether the agency is prepared to deal with new variants, about the use and effectiveness of booster vaccines, clinical trials transparency and coordination with European and international counterparts, including the new Health Emergency Preparedness and Response Authority (HERA).


    Emer Cooke, Executive Director of the European Medicines Agency (EMA) reassured MEPs that the EMA is prepared to deal with the current challenges posed by the pandemic. Existing vaccines have remained effective until now, with studies showing that an additional dose or booster ensures extended immunity, she added. Should a scientific decision be taken to adapt them, the Agency already has in place guidance for manufacturers that plan to modify vaccines to address variants. The agency also has a legal framework to authorise adapted vaccines more quickly, which would ensure they are approved within a 3-4 months period.


    The EMA recently recommended that a booster dose of the two mRNA-based COVID-19 vaccines (Comirnaty-BioNTech/Pfizer and Spikevax - Moderna) may be given to people with severely weakened immune systems as well as the general population over 18 years old, said Emer Cooke. Member states decide how these boosters should be rolled out depending on their vaccination campaigns and the capacity of their national health systems.


    Regarding clinical trials, Ms Cooke confirmed that the EMA is committed to being transparent in publishing data, also in view of the application of the new requirements under the clinical trials regulation from the end of January 2022. On coordination with HERA, the EMA is currently preparing a memorandum of understanding, which will clearly outline the responsibilities of the two bodies and ensure they coordinate effectively.


    With regard to the EMA’s capacity to deal with its reinforced role, Ms Cooke informed MEPs that the Agency is still evaluating the impact of its new tasks. However, the general situation is a concern, with the workload constantly growing since 2014 and the needs of human resources not being matched with financial resources.


    Background


    The Environment, Public Health and Food Safety MEPs hold annual exchanges with leaders of EU agencies within the committee’s fields of expertise. Parliament and Council also recently reached a deal for a stronger role for the Agency following lessons learned from the pandemic.

    In light of increasing COVID-19 cases across the EU and concerns raised by a new variant, members of the Environment, Public Health and Food Safety Committee focused the debate on COVID-19 vaccines, recent developments in COVID-19 therapeutics and the Agency’s capacity to deal with current and future challenges. MEPs asked whether the agency is prepared to deal with new variants, about the use and effectiveness of booster vaccines, clinical trials transparency and coordination with European and international counterparts, including the new Health Emergency Preparedness and Response Authority (HERA).

    new variantCOVID-19 vaccinesCOVID-19 therapeutics


    Emer Cooke, Executive Director of the European Medicines Agency (EMA) reassured MEPs that the EMA is prepared to deal with the current challenges posed by the pandemic. Existing vaccines have remained effective until now, with studies showing that an additional dose or booster ensures extended immunity, she added. Should a scientific decision be taken to adapt them, the Agency already has in place guidance for manufacturers that plan to modify vaccines to address variants. The agency also has a legal framework to authorise adapted vaccines more quickly, which would ensure they are approved within a 3-4 months period.


    European Medicines Agencyguidance for manufacturerslegal framework


    The EMA recently recommended that a booster dose of the two mRNA-based COVID-19 vaccines (Comirnaty-BioNTech/Pfizer and Spikevax - Moderna) may be given to people with severely weakened immune systems as well as the general population over 18 years old, said Emer Cooke. Member states decide how these boosters should be rolled out depending on their vaccination campaigns and the capacity of their national health systems.


    Comirnaty-BioNTech/PfizerSpikevax - Moderna


    Regarding clinical trials, Ms Cooke confirmed that the EMA is committed to being transparent in publishing data, also in view of the application of the new requirements under the clinical trials regulation from the end of January 2022. On coordination with HERA, the EMA is currently preparing a memorandum of understanding, which will clearly outline the responsibilities of the two bodies and ensure they coordinate effectively.


    clinical trials regulation


    With regard to the EMA’s capacity to deal with its reinforced role, Ms Cooke informed MEPs that the Agency is still evaluating the impact of its new tasks. However, the general situation is a concern, with the workload constantly growing since 2014 and the needs of human resources not being matched with financial resources.


    its reinforced role


    Background


    Background


    The Environment, Public Health and Food Safety MEPs hold annual exchanges with leaders of EU agencies within the committee’s fields of expertise. Parliament and Council also recently reached a deal for a stronger role for the Agency following lessons learned from the pandemic.


    deal for a stronger role for the Agency

    Contact: 

    Contact: 
    Contact: 
  • Dana POPP 

    Dana POPP Dana POPP 
    Press Officer 
    Press Officer Press Officer 
    Contactgegevens: 
    Contactgegevens: 
  • Telefoonnummer: (+32) 2 28 46330 (BXL) 
  • Telefoonnummer: (+32) 2 28 46330 (BXL) Telefoonnummer: (+32) 2 28 46330 (BXL)Telefoonnummer: (BXL) 
  • Telefoonnummer: (+33) 3 881 74903 (STR) 
  • Telefoonnummer: (+33) 3 881 74903 (STR) Telefoonnummer: (+33) 3 881 74903 (STR)Telefoonnummer: (STR) 
  • Mobiel telefoonnummer: (+32) 470 95 17 07 
  • Mobiel telefoonnummer: (+32) 470 95 17 07 Mobiel telefoonnummer: (+32) 470 95 17 07Mobiel telefoonnummer:  
  • E-mail: dana.popp@europarl.europa.eu 
  • E-mail: dana.popp@europarl.europa.eu E-mail: dana.popp@europarl.europa.euE-mail:  
  • E-mail: envi-press@europarl.europa.eu 
  • E-mail: envi-press@europarl.europa.eu E-mail: envi-press@europarl.europa.euE-mail:  
  • Twitteraccount: @EP_Environment 
  • Twitteraccount: @EP_Environment Twitteraccount: @EP_EnvironmentTwitteraccount:  
     
     

    Further information 

    Further information 
    Further information 
  • Recording of the debate  Recording of the debate 
  • Video extracts from the debate  Video extracts from the debate 
  • Latest updates on the COVID-19 pandemic from the European Medicines Agency  Latest updates on the COVID-19 pandemic from the European Medicines Agency 
  • EMA - Mid-year report (January - June 2021)   EMA - Mid-year report (January - June 2021)  
  • COVID-19 Vaccine Tracker (ECDC)  COVID-19 Vaccine Tracker (ECDC) 
  • Free photos, video and audio material  Free photos, video and audio material 
     
     
     
     
     

    Productinformatie 

    REF.:  20211129IPR18310 

    Productinformatie 

    Productinformatie 
    Productinformatie 
    Productinformatie 
    REF.:  20211129IPR18310 
    REF.:  20211129IPR18310 
    REF.: REF.:REF.: 20211129IPR18310 20211129IPR18310 

    Deel deze pagina: 

    Deel deze pagina: 
    Deel deze pagina: 
  • Facebook Facebook 
  • Twitter Twitter 
  • LinkedIn LinkedIn 
  • Whatsapp Whatsapp Aanmelden voor e-mailupdatesAanmelden voor e-mailupdatesPdf-versie Pdf-versie 

    Voettekst 

    Voettekst Nieuws  Bekijk het menu: nieuws  Bekijk het menu: nieuws 
    Het Parlement in uw land 
  • Brussels  
  • Brussels   Brussels 
  • Den Haag  
  • Den Haag   Den Haag Tools 
  • Wetgevingsobservatorium  
  • Wetgevingsobservatorium   Wetgevingsobservatorium 
  • Multimedia Centre  
  • Multimedia Centre   Multimedia Centre 
  • EbS  
  • EbS   EbS 
    De Voorzitter van het Europees Parlement 
  • Webpagina van de Voorzitter van het Parlement  
  • Webpagina van de Voorzitter van het Parlement   Webpagina van de Voorzitter van het Parlement  Menu verbergen: Nieuws   Menu verbergen: Nieuws Europees Parlement  Menu bekijken: Europees Parlement   Menu bekijken: Europees Parlement 
  • Nieuws 
  • Nieuws  Nieuws 
  • Leden 
  • Leden  Leden 
  • Over het Parlement 
  • Over het Parlement  Over het Parlement 
  • Plenaire vergadering 
  • Plenaire vergadering  Plenaire vergadering 
  • Commissies 
  • Commissies  Commissies 
  • Delegaties 
  • Delegaties  Delegaties Menu verbergen: Europees Parlement Menu verbergen: Europees Parlement  

    Het Parlement in de sociale media  

    Het Parlement in de sociale media 
  • Facebook  
  • Facebook   Facebook 
  • Twitter  
  • Twitter   Twitter 
  • Facebook  
  • Facebook   Facebook 
  • LinkedIn  
  • LinkedIn   LinkedIn 
  • YouTube  
  • YouTube   YouTube 
  • Instagram  
  • Instagram   Instagram 
  • Pinterest  
  • Pinterest   Pinterest 
  • Snapchat  
  • Snapchat   Snapchat 
  • Reddit  
  • Reddit   Reddit Informatieve links 
  • Contact 
  • Contact Contact 
  • RSS 
  • RSS RSS 
  • Sitemap 
  • Sitemap Sitemap 
  • Juridische mededeling 
  • Juridische mededeling Juridische mededeling 
  • Privacybeleid 
  • Privacybeleid Privacybeleid 
  • Toegankelijkheid 
  • Toegankelijkheid Toegankelijkheid